Protalix sees $3.2B Fabry market by 2031 while targeting PRX-115 Phase II top-line results in H2 next year (NYSE:PLX)

Protalix (PLX) Q3 2026 Earnings Call Transcript

Elfabrio sales lifted revenue as PRX-119 trial timing comes into focus.

Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript

Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call November 9, 2026 4:30 PM ESTCompany ParticipantsGitanjali Ogawa - VP & Head of Investor...

Protalix BioTherapeutics Q3 2026 Earnings Call Transcript

Protalix BioTherapeutics (AMEX:PLX) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

NEW YORK--(BUSINESS WIRE)-- #GAD--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended September 30, 2026, and recent highlights. The Company also reported positive initial results from more...

Abeona Therapeutics Inc. (ABEO) Q3 2026 Earnings Call Transcript

Follow Abeona Therapeutics Inc. (ABEO) Q3 2026 Earnings Call November 9, 2026 8:30 AM EST Company Participants Gregory Gin – Vice President of Investor Relations & Corporate CommunicationsVishwas Seshadri – President, CEO & DirectorMadhav Vasanthavada – SVP, Chief Commercial Officer & Head of Business DevelopmentJoseph Vazzano – Chief Financial Officer Conference Call Participants Mohamad Amin Makarem – Jefferies LLC, Research DivisionRaghura…